Nemaura Reports Third Quarter 2018 Financial Results

- February 12th, 2019

Nemaura Medical (NASDAQ:NMRD) has announced its financial results for Q3 ended December 30, 2018. As quoted in the press release: Recent Highlights and Accomplishments: •           Nemaura Signed License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar •           Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission •           Nemaura Raised … Continued

Nemaura Medical (NASDAQ:NMRD) has announced its financial results for Q3 ended December 30, 2018.

As quoted in the press release:

Recent Highlights and Accomplishments:

•           Nemaura Signed License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar

•           Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission

•           Nemaura Raised Circa $2M in Public Offering

•           Nemaura Completed Key Stages of Technical File Review for SugarBEAT® CE Mark Approval

•           Nemaura Announced Improvements to SugarBEAT® Warm Up Period  

•           Nemaura Announced Grant of U.S. Patent for SugarBEAT®

•           Nemaura Announced Dr. Fred Schaebsdau to Lead Strategy and Business Development

Dr. Faz Chowdhury, CEO of Nemaura Medical, commented, “Over the past quarter, we have bolstered our financial position to better support the upcoming commercial launch of SugarBEAT® and filing of our FDA 510(k) submission.”

Click here to read the full press release.

 

New FREE Report: Investing in Psychedelics

   
What’s ahead for this exciting new segment? Learn more with our exclusive psychedelics report today. Published July 6, 2020.
 

Leave a Reply